Moderna Inc. said Thursday a Phase 3 trial of its next-generation COVID-19 vaccine met its main goal and showed higher efficacy in adults age 18 and older compared with its original vaccine, Spikevax.

Northwestern filed a lawsuit against Moderna Wednesday alleging the company misused the University’s patented lipid nanoparticles to develop its SpikeVax COVID-19 vaccine. NU had a critical role ...

SPIKEVAX (COVID-19 Vaccine, mRNA) is a vaccine indicated for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV ...

mRNA-1283 met its primary vaccine efficacy endpoint in a Phase 3 trial, demonstrating non-inferior vaccine efficacy against COVID-19 compared to Spikevax® in participants 12 years of age and ...

The lawsuit said, opens new tab Moderna uses Northwestern-developed lipid nanoparticle (LNP) technology without a license in Spikevax shots to transport fragile messenger RNA into the human body.

They received either the combination vaccine or were co-administered the on-the-market flu vaccine, Fluarix and Spikevax. When compared with the existing vaccines in both age groups, Moderna's ...

The biotech company said Monday it expects between $1.5 billion and $2.5 billion in revenue in 2025, mostly in the second half of the year due to Spikevax and mRESVIA vaccine sales. Analysts ...

Languages: English. The company, known for its COVID-19 vaccine, Spikevax, said it expects revenue to range between $1.5 billion and $2.5 billion in 2025, compared to as much as $3.1 billion in ...

The biotech company, which makes the Spikevax RNA-based Covid-19 vaccine, posted a net loss of $971 million, compared with a loss of $1.18 billion a year earlier. On a per-share basis, the company ...

Into this situation, Moderna launched Spikevax, its branded COVID product. To combat the challenges of COVID fatigue, declining brand engagement and a well-heeled competitor with celebrity-driven ...

Spikevax. A consistent trend was seen in a subset of adults age 65 and older, the company said in a statement. Back To Top ...